Centruroides Immune Fab2
Centruroides Immune Fab2 Uses, Dosage, Side Effects, Food Interaction and all others data.
Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 fragments that are derived from plasma of the horses immunized with venom of C. noxius, C. l. limpidus, C. l. tecomanus, and C. s. suffusus. It is intravenously administered patients with clinical signs of scorpion envenomation so that the Fab fragments bind to the toxins and limit systemic toxicity. It was approved by FDA in 2011 and is marketed under the name Anascorp .
Anascorp is produced from equine IgG antibodies. Because initial development and use of this product in Mexico, venoms from several Centruroides species endemic to Mexico are pooled and diluted .
This drug is a polyvalent antivenin proven to be useful against scorpion stings.It is the first specific treatment to neutralize toxin from Centruroides scorpion stings, particularly those of the Centruroides sculpturatus in the United States .
| Trade Name | Centruroides Immune Fab2 |
| Generic | Scorpion (centruroides) immune Fab2 antivenin (equine) |
| Scorpion (centruroides) immune Fab2 antivenin (equine) Other Names | Antivenin, scorpion, Antivenin,centruroides immune Fab2, Centruroides (scorpion) Immune F(ab')2 (equine), Centruroides (scorpion) immune F(ab')2 (equine) injection, Centruroides (scorpion) immune F(ab)2 intravenous (equine), Centruroides (scorpion) immune Fab2 (equine), Centruroides antivenin, Centruroides antivenin (equine), Centruroides Fab2 antivenin (equine), Centruroides suffusus suffusus) (equine), Mexican scorpion (centruroides) Fab2 antivenin (equine), Polyvalent mexican scorpion antivenin (horse), Scorpion (centruroides) Fab2 immunoglobulin (equine) |
| Type | |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Centruroides Immune Fab2 is a purified preparation of immunoglobulin gamma antibodies used to treat scorpion stings.
Indicated for treatment of clinical signs of scorpion envenomation , .
Centruroides Immune Fab2 is also used to associated treatment for these conditions: Venom poisoning caused by Scoprion
How Centruroides Immune Fab2 works
Anascorp, the trade name of this drug, is composed of venom-specific F(ab’)2 fragments of immunoglobulin G (IgG) that bind to and neutralize venom toxins, promoting redistribution away from target tissues and subsequent elimination from the body .
Toxicity
The most common adverse reactions observed in ≥ 2% of patients in the clinical studies for Anascorp were: vomiting, pyrexia, rash, nausea, and pruritus .
Severe hypersensitivity reactions, including anaphylaxis, may occur with Anascorp , . Diligent patient monitoring for hypersensitivity reactions and preparation for intravenous therapy using epinephrine, corticosteroids, and diphenhydramine hydrochloride is recommended during the infusion. If an anaphylactic reaction occurs during the Anascorp infusion, case administration immediately, and administer warranted emergency medical care .
Patients with existing allergies to horse protein are at a higher risk for developing anaphylactic reactions. Patients who have had previous therapy with Anascorp or another equine antivenom/antitoxin may have become sensitized to equine proteins and be at an elevated risk for a severe hypersensitivity reaction .
Trace amounts of cresol from the manufacturing process are contained in Anascorp. Localized reactions and generalized myalgias have been observed with the use of cresol as an injectable excipient .
Monitor patients with follow-up visit(s) for signs and symptoms of delayed allergic reactions or serum sickness (symptoms include rash, fever, myalgia, arthralgia), and treat appropriately if necessary. Eight out of 1,534 (0.5%) patients in the clinical trials exhibited symptoms suggestive of serum sickness .
Anascorp is created from equine (horse) plasma, it may carry a risk of transmitting infectious agents, e.g., viruses .
The following adverse reactions have been identified during post-approval use of Anascorp: chest tightness, palpitations, rash, and pruritus. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure .
Food Interaction
No interactions found.Volume of Distribution
Steady state: 13.6 ± 5.4 L .
Half Life
159 ± 57 h .
Clearance
83.5 ± 38.4 ml/Hr
Innovators Monograph
You find simplified version here Centruroides Immune Fab2
